settlement

Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.

The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for  patients who had not been in remission for five years and who had not been taking tamoxifen.

The deal ends an investigation by the SEC into certain accounting practices by Alere's foreign subsidiaries. The company also consented to a cease-and-desist order. 

The firms have eliminated several terms of their original deal and have cross-licensed IP to allow Med BioGene to license Gene FX Lung to other firms. 

As part of a settlement deal, Siemens will pay Enzo an upfront fee of $9.5 million and potentially up to $5 million in licensing royalties.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Myriad and Quest have agreed to dismiss lawsuits, claims, counterclaims, and disputes related to Myriad's patent claims on BRCA1 and BRCA2 in the litigation.

NEW YORK (GenomeWeb) – CareDx said after the close of the market on Wednesday that it has settled a dispute with Roche over a licensing agreement forged between the two firms in late 2004.

Just days before they were scheduled to go to trial, Alnylam Pharmaceuticals and Tekmira Pharmaceuticals announced that they have hammered out a settlement to their protracted patent-infringement and technology-misappropriation lawsuits.

NEW YORK (GenomeWeb News) – Genetic Technologies today announced it has reached a settlement and licensing agreement with GeneSeek, resolving a patent dispute between the firms.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.